Providing perspective on the departure of Principal Deputy Commissioner Joshua Sharfstein from FDA, Ms. Myers comments on the leadership and expertise that Sharfstein’s interim replacement, John Taylor III, will bring to the role. Ms. Myers also comments on the industry view of the principal deputy commissioner’s role in general, and the rationale for various choices Commissioner Hamburg has in terms of filling the role permanently.

“Hamburg Taps Advisor as Sharfstein Interim Replacement”

Drug Industry Daily

(subscription required)